**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 83284

**Manuscript Type:** MINIREVIEWS

**Etiopathogenic theories about long COVID**

Del Carpio-Orantes L. Theories about long COVID

Luis Del Carpio-Orantes

**Luis Del Carpio-Orantes,** Department of Internal Medicine, Virology, Research, Study Group for the Diagnosis and Treatment of COVID-19 in Veracruz, Veracruz 91900, Veracruz, Mexico

**Author contributions:** Del Carpio-Orantes L contributed to conceptualized the idea of the review, searched for information for the review, wrote the document, provided a summary of the information on the diagnosis and treatment chart.

**Corresponding author: Luis Del Carpio-Orantes, MD, Research Scientist,** Department of Internal Medicine, Virology, Research, Study Group for the Diagnosis and Treatment of COVID-19 in Veracruz, 12 de Octubre 603, Veracruz 91900, Veracruz, Mexico. neurona23@hotmail.com

**Received:** January 15, 2023

**Revised:** April 8, 2023

**Accepted:** May 12, 2023

**Published online:**

**Abstract**

The main etiopathogenic theories of long coronavirus disease (COVID) are listed and a conjunction of them is carried out with the objective of deciphering the pathophysiology of the entity, finally the main lines of treatment existing in real life are discussed (Paxlovid, use of antibiotics in dysbiosis, triple anticoagulant therapy, temelimab).

**Key Words:** Long COVID; Viral persistence; Amyloid microthrombosis; Dysbiosis; Weakened immune system; Paxlovid; Triple therapy

Del Carpio-Orantes L. Etiopathogenic theories about long COVID. *World J Virol* 2023; In press

**Core Tip:** List the main etiopathogenic theories of long coronavirus disease (COVID) and evaluate their interrelation as pathophysiological agents of long COVID syndrome.

**INTRODUCTION**

Long coronavirus disease (COVID) is broadly defined as signs, symptoms, and conditions that continue or develop after initial COVID-19 or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The signs, symptoms, and conditions are present four weeks or more after the initial phase of infection; may be multisystemic; and may present with a relapsing– remitting pattern and progression or worsening over time, with the possibility of severe and life-threatening events even months or years after infection; this being the definition adjusted by the Centers for Disease Control and Prevention's, since the previous definition of the World Health Organization mentioned persistent symptoms after 12 wk[1].

However, for all these etiopathogenic processes that define long COVID to occur, there is still no specific evidence on it and various theories have been created that try to decipher the pathophysiology of said entity, some are independent, but others have strong ties between them. And depend on each other, the main etiopathogenic theories of long COVID are mentioned below:

Theory of viral persistence or viral particles: There is evidence that after an acute episode of COVID-19, there is persistence of viral particles in various organs up to one year after the episode and the organs mainly affected are: Brain, Gastrointestinal and Hemolymphatic; Similarly, they have been detected in blood, feces and urine[2,3].

Theory of endothelial dysfunction: This theory deals with the damage to the vascular endothelium that leads to endothelitis which, in turn, will favor platelet increase and activation, increased risk of thrombus formation with subsequent damage to organs and tissues by a mechanism of tissue ischemia that can affect the main organs and systems of the human body[4,5].

Theory of platelet hyperactivity: which is related to the previous theory and mentions that this hyperactivity favors the formation of microthrombi which have the characteristic of being amyloid and in this area, is linked to the theory of viral persistence which mentions that protein S has amyloidogenesis potential, which makes these amyloid thrombi more resistant to degradation and more hard, which ensures occlusion of the microvasculature with subsequent diverse organic damage (highlights tissue destruction and damage to central and peripheral nerves)[6-8].

Crucial nerve damage theory: This theory ties in with the previous one and refers to damage to nerves crucial to the functioning of the autonomic nervous system, such as damage to the vagus nerve, which controls various functions of the cardiovascular systems, gastrointestinal and pulmonary, so damage to it can cause many symptoms in these systems[9].

Theory of immune abnormalities: after an acute COVID-19 case, there is evidence of persistent inflammation that feeds the inflammasome of each person, in addition to the presence of autoimmunity that adds various comorbidities to the patients and even the *de novo* appearance of rheumatological diseases such as lupus, dermatomyositis, rheumatoid arthritis, *etc.* In addition, the production of antibodies against the angiotensin converting enzyme-2 (ACE2) receptor has been demonstrated that could decrease the activity of ACE2, both in the soluble part and in the membrane-bound part, which would finally activate the immune system, which can act as immunological priming by molecular mimicry. In the same way, an “exhaustion of the immune system after an acute COVID-19 condition has been demonstrated, which conditions a decrease in lymphocyte subpopulations and the subsequent risk of opportunistic diseases[10-14].

Theory of interaction with subclinical viruses: This theory mentions that after the maladjustment of the immune system produced by acute COVID-19, some viruses that tend to remain in a subclinical form (mainly those of the herpesviridae family), can be activated again by adding morbidity to the long COVID picture, with various symptoms according to the viral type[15-17].

Dysbiosis Theory: this theory mentions that patients with Long COVID present a dysbiosis which would hinder the relationships between the microbiota and the virome, favoring symptoms of the main organ systems and systems, highlighting the involvement of the respiratory system and the gastrointestinal system (Which have a large number of ACE2 and transmembrane serine protease 2 receptors that favor viral entry into cells), which are the main ones that harbor the microbiota, conditioning dysbiosis[18,19].

Theory of aggravation of chronic diseases or de novo appearance of chronic diseases: in this etiopathogenic theory it is mentioned that diseases previously diagnosed with an acute picture of COVID-19 can get out of control or worsen concomitantly, which adds greater comorbidity to the patient both in the acute stage as in long COVID; It has also been seen that after the acute picture, many patients develop chronic degenerative diseases such as: Diabetes, Hypertension, various Cardiopathies, Dementias, Thyroid diseases, *etc*[20-26]*.*

Once the main theories have been described, we will try to put them together in order to be able to describe pathophysiology.

In recent times, viral persistence has stood out, mainly of the S and N proteins that greatly affect the central and autonomic nervous system, coupled with the neurotropism of SARS COV-2 that causes damage to the nervous system and the vagus nerve, hence the main manifestations are neuropsychiatric; protein S has the particularity of conditioning amyloidogenesis together with the presence of amyloid peptide A product of inflammation in the acute stage, which could lead to the presence of amyloid microthrombi, perpetuating both inflammation and thrombotic risk; in aggregate form, these characteristics can condition both positive and negative immune deregulation; positive deregulation would increase the activity of the immune system conditioning autoimmunity while negative deregulation is associated with completeness of the system with disorder of B, T and NK cell lines, the latter reveals the reactivation of latent viruses that increase morbidity as well as the virome, causing an imbalance between it and the intestinal microbiota, giving way to the theory of dysbiosis, which is associated, in addition to gastrointestinal symptoms, to neuropsychiatric and cardiovascular disorders, even leading to dysautonomia and hormonal changes, leading to a vicious circle.

There are currently many researcher-led treatment efforts and initiatives, notably the following:

Dr. Iwasaki from Yale University, leads a clinical study using Paxlovid in these patients affected by Long COVID, based on the theory of viral persistence, who receive the antiviral for 15 days waiting for symptomatic improvement, the study is still recruiting participants and promising results are expected (ClinicalTrials.gov Identifier: NCT05668091)[27].

Other researchers led by Dr. Etheresia Pretorius, are addressing the theory of immunothrombosis, in which they have demonstrated the presence of amyloid microthrombi and initiated a special therapy called Triple therapy, which uses direct oral anticoagulants, dual antiplatelet therapy, and gastric protection, from which encouraging results are expected[28,29].

Other research efforts fall on two researchers, Tamara Romanuk and Ale Frost, who address the theory of dysbiosis secondary to long COVID and that it conditions a gut-brain axis disorder with subsequent neuropsychiatric dysfunction (@remissionbiome on twitter); In their study, they have implemented the study of the microbiota and are using a treatment scheme with the antibiotics doxycycline and amoxicillin with clavulanate, taking advantage of properties against neuroinflammation and neuroimmunology; something similar occurs with the study of dectin-1 as a therapeutic target for the treatment of stress-induced behaviors[30,31].

In Spain, researchers address the theory of damage to the vagus nerve in patients with long COVID, based on the prevalence of inappropriate sinus tachycardia in these patients, they have devised an ultrasound protocol to identify vagus nerve disorders, which would corroborate the viral neurotropism that affects to said nerve, conditioning dysautonomia and disorders in other spheres such as neuropsychiatric, cardiopulmonary, gastrointestinal and endocrinological[32].

Finally, in Switzerland, a research protocol has begun with a monoclonal antibody called Temelimab focused on chronic fatigue and cognitive alterations, whose target is a protein called HERV-W-End, which has been associated with autoimmune diseases and chronic fatigue; encouraging results are expected for long COVID patients. The investigation has been extended to Spain and Italy (ClinicalTrials.gov Identifier: NCT05497089)[33].

**CONCLUSION**

There is still much to be deciphered in the etiopathogenesis and pathophysiology of long COVID, however current efforts clarify these conditions on which treatments are tested in the real world, in order to limit the pathological manifestations that affect the population affected by long COVID. With the study of etiopathogenic theories, diagnostic and treatment strategies can begin to be created (Table 1).

**REFERENCES**

1 **Department of Health and Human Services,** Office of the Assistant Secretary for Health. 2022. National Research Action Plan on Long COVID, 200 Independence Ave SW, Washington, DC 20201 [DOI: 10.1037/e304752003-001]

2 **Tejerina F**, Catalan P, Rodriguez-Grande C, Adan J, Rodriguez-Gonzalez C, Muñoz P, Aldamiz T, Diez C, Perez L, Fanciulli C, Garcia de Viedma D; Gregorio Marañon Microbiology ID COVID 19 Study Group. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. *BMC Infect Dis* 2022; **22**: 211 [PMID: 35240997 DOI: 10.1186/s12879-022-07153-4]

3 **Swank Z**, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. *Clin Infect Dis* 2023; **76**: e487-e490 [PMID: 36052466 DOI: 10.1093/cid/ciac722]

4 **Willyard C**. Could tiny blood clots cause long COVID's puzzling symptoms? *Nature* 2022; **608**: 662-664 [PMID: 36002482 DOI: 10.1038/d41586-022-02286-7]

5 **Charfeddine S**, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R, Bahloul A, Kallel N, Moussa N, Touil I, Ghrab A, Elghoul J, Meddeb Z, Thabet Y, Kammoun S, Bouslama K, Milouchi S, Abdessalem S, Abid L. Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study. *Front Cardiovasc Med* 2021; **8**: 745758 [PMID: 34917659 DOI: 10.3389/fcvm.2021.745758]

6 **Kell DB**, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. *Biochem J* 2022; **479**: 537-559 [PMID: 35195253 DOI: 10.1042/BCJ20220016]

7 **Pretorius E**, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. *Cardiovasc Diabetol* 2021; **20**: 172 [PMID: 34425843 DOI: 10.1186/s12933-021-01359-7]

8 **Nyström S**, Hammarström P. Amyloidogenesis of SARS-CoV-2 Spike Protein. *J Am Chem Soc* 2022; **144**: 8945-8950 [PMID: 35579205 DOI: 10.1021/jacs.2c03925]

9 **Papadopoulou M**, Bakola E, Papapostolou A, Stefanou MI, Gaga M, Zouvelou V, Michopoulos I, Tsivgoulis G. Autonomic dysfunction in long-COVID syndrome: a neurophysiological and neurosonology study. *J Neurol* 2022; **269**: 4611-4612 [PMID: 35536408 DOI: 10.1007/s00415-022-11172-1]

10 **Calabrese C**, Kirchner E, Calabrese LH. Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications. *Best Pract Res Clin Rheumatol* 2022: 101794 [PMID: 36369208 DOI: 10.1016/j.berh.2022.101794]

11 **Merad M**, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. *Science* 2022; **375**: 1122-1127 [PMID: 35271343 DOI: 10.1126/science.abm8108]

12 **Arthur JM**, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. *PLoS One* 2021; **16**: e0257016 [PMID: 34478478 DOI: 10.1371/journal.pone.0257016]

13 **Proal AD**, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. *Front Microbiol* 2021; **12**: 698169 [PMID: 34248921 DOI: 10.3389/fmicb.2021.698169]

14 **Rha MS**, Shin EC. Activation or exhaustion of CD8(+) T cells in patients with COVID-19. *Cell Mol Immunol* 2021; **18**: 2325-2333 [PMID: 34413488 DOI: 10.1038/s41423-021-00750-4]

15 **Algaadi SA**. Herpes zoster and COVID-19 infection: a coincidence or a causal relationship? *Infection* 2022; **50**: 289-293 [PMID: 34807403 DOI: 10.1007/s15010-021-01714-6]

16 **Gold JE**, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. *Pathogens* 2021; **10** [PMID: 34204243 DOI: 10.3390/pathogens10060763]

17 **Peluso MJ**, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, Chan F, Lu S, Goldberg SA, Hoh R, Tai V, Torres L, Iyer NS, Deswal M, Ngo LH, Buitrago M, Rodriguez A, Chen JY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Deitchman AN, Hellmuth J, Spinelli MA, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Deeks SG, Hunt PW, Henrich TJ. Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID. *medRxiv* 2022 [PMID: 35898346 DOI: 10.1101/2022.06.21.22276660]

18 **Wang B**, Zhang L, Wang Y, Dai T, Qin Z, Zhou F, Zhang L. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. *Signal Transduct Target Ther* 2022; **7**: 143 [PMID: 35487886 DOI: 10.1038/s41392-022-00986-0]

19 **Haran JP**, Bradley E, Zeamer AL, Cincotta L, Salive MC, Dutta P, Mutaawe S, Anya O, Meza-Segura M, Moormann AM, Ward DV, McCormick BA, Bucci V. Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. *JCI Insight* 2021; **6** [PMID: 34403368 DOI: 10.1172/jci.insight.152346]

20 **Asadi-Pooya AA**, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, Barzegar Z, Kabiri M, Zeraatpisheh Z, Farjoud-Kouhanjani M, Jafari A, Sasannia S, Ashrafi S, Nazeri M, Nasiri S, Shahisavandi M. Long COVID syndrome-associated brain fog. *J Med Virol* 2022; **94**: 979-984 [PMID: 34672377 DOI: 10.1002/jmv.27404]

21 **Prieto Rodríguez MÁ**, March Cerdá JC, Martín Barato A, Escudero Carretero M, López Doblas M, Luque Martín N. [Consequences of the COVID-19 lockdown in patients with chronic diseases in Andalusia]. *Gac Sanit* 2022; **36**: 139-145 [PMID: 33342601 DOI: 10.1016/j.gaceta.2020.11.001]

22 **Raveendran AV**, Misra A. Post COVID-19 Syndrome ("Long COVID") and Diabetes: Challenges in Diagnosis and Management. *Diabetes Metab Syndr* 2021; **15**: 102235 [PMID: 34384972 DOI: 10.1016/j.dsx.2021.102235]

23 **Burekovic A**, Halilovic D, Sahbaz A. Hypothyroidism and Subclinical Hypothyroidism as a Consequence of COVID-19 Infection. *Med Arch* 2022; **76**: 12-16 [PMID: 35422565 DOI: 10.5455/medarh.2022.76.12-16]

24 **Raman B**, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. *Eur Heart J* 2022; **43**: 1157-1172 [PMID: 35176758 DOI: 10.1093/eurheartj/ehac031]

25 **Premraj L**, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, Suen J, Robba C, Fraser J, Cho SM. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. *J Neurol Sci* 2022; **434**: 120162 [PMID: 35121209 DOI: 10.1016/j.jns.2022.120162]

26 **Davis HE**, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023; **21**: 133-146 [PMID: 36639608 DOI: 10.1038/s41579-022-00846-2]

27 The Yale Paxlovid for Long COVID (PAX LC) Trial. https://medicine.yale.edu/cii/research/paxlc-study/

28 **Pretorius E**, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, Rajaratnam K, Watson BW, Kell DB. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). *Cardiovasc Diabetol* 2022; **21:** 148 [PMID: 35933347 DOI: 10.1186/s12933-022-01579-5]

29 **Nunes JM**, Kell DB, Pretorius E. Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses. *Blood Rev* 2023: 101075 [PMID: 36963989 DOI: 10.1016/j.blre.2023.101075]

30 **Ladyzhets B**. Chronic fatigue syndrome is a puzzle. Your gut microbiome may have the key. Nationalgeographic magazine. Published march 9, 2023. Available from: https://www.nationalgeographic.com/magazine/article/chronic-fatigue-syndrome-gut-microbiome-may-have-the-key

31 **Zhu X**, Sakamoto S, Ishii C, Smith MD, Ito K, Obayashi M, Unger L, Hasegawa Y, Kurokawa S, Kishimoto T, Li H, Hatano S, Wang TH, Yoshikai Y, Kano SI, Fukuda S, Sanada K, Calabresi PA, Kamiya A. Dectin-1 signaling on colonic γδ T cells promotes psychosocial stress responses. *Nat Immunol* 2023; **24**: 625-636 [PMID: 36941398 DOI: 10.1038/s41590-023-01447-8]

32 **Aranyó J**, Bazan V, Lladós G, Dominguez MJ, Bisbal F, Massanella M, Sarrias A, Adeliño R, Riverola A, Paredes R, Clotet B, Bayés-Genís A, Mateu L, Villuendas R. Inappropriate sinus tachycardia in post-COVID-19 syndrome. *Sci Rep* 2022; **12:** 298 [PMID: 34996973 DOI: 10.1038/s41598-021-03831-6]

33 **Mouliou DS**, Dardiotis E. Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? *Mult Scler Relat Disord* 2022; **64**: 103938 [PMID: 35717898 DOI: 10.1016/j.msard.2022.103938]

**Footnotes**

**Conflict-of-interest statement:** The author declares no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 15, 2023

**First decision:** March 1, 2023

**Article in press:**

**Specialty type:** Virology

**Country/Territory of origin:** Mexico

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Fabbri N, Italy; Wang D, Thailand **S-Editor:** Liu JH **L-Editor:** A **P-Editor:**

**Table 1 Diagnosis and treatment based on the theories of long coronavirus disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Pathological condition to study** | **Clinic** | **Basic diagnostic method** | **Extension studies** | **Treatments** |
| **Neuropsychiatric manifestations** | Anxiety Depression headache; brain fog; early dementia Fatigue/weakness/myasthenia Mitochondriopathy suspected | Psychological tests; Clinical questioning Neurological examination | Cranial CT head MRI brain PET scan CSF analysis; Electroencephalogram EMG/CNV; Serum lactate-pyruvate/CSF | Psychological therapy Psychiatric treatment Pacing; Brain Electrostimulation; Speech therapy; Behavioral therapy |
| **Viral persistence** | Leukopenia, lymphopenia Virus reactivation (Herpes, EBV); Persistently positive COVID tests | Nasal COVID antigen (or PCR-RT); IgM-IgG serology for Herpes, CMV, EBV | Total body PET to viral reservoirs, RT-PCR for Sars Cov2: Serum; Urinary; Stool | Antivirals: Paxlovid (Yale trial); Oral remdesivir; Acyclovir, Ganciclovir |
| **Immunothrombosis** | Clinical data of inflammation or thrombosis: Arthralgias/Arthritis; Myalgias; Arterial/venous thrombosis | D-dimer Ferritin; C Reactive Protein Reactive thrombocytosis DHL; Creatine phosphokinase Myoglobin | Intentional search for amyloid microthrombi: Immunofluorescence microscopy; Flow cytometry; Alpha 2 antiplasmin; Serum amyloid A Platelet hyperactivation; Platelet aggregometry | Triple therapy: Oral anticoagulants; Dual antiplatelet; Gastric protection. Fibrinolytics Chelators Vitamins |
| **Immune dysregulation** | Frequent infections; De novo appearance of autoimmune diseases | Leukopenia, Lymphopenia Reactive lymphocytosis | Lymphocyte subpopulation; CD4/CD8/Natural killers; Miscellaneous and specific antibodies | Immunomodulators Immunostimulants Biological therapy; Monoclonal antibodies (Temelimab) |
| **Vagus nerve injury** | Brain fog Dysautonomias | Electrocardiogram Holter; Ambulatory Blood Pressure Monitoring | Vagus nerve ultrasound Tilted table test | Electrostimulation of the vagus nerve; Cardiac rehabilitationPyridostigmine |
| **Dysbiosis** | Brain fog Depression/anxiety Irritable colon Chronic diarrhea | Coprological Stool culture | Intestinal dysbiosis test Stool calprotectin Dysbiosis specific Kits: Gastrotest; GI effects; Healthy gut | Nutritional treatment Prebiotics; Antibiotics (doxycycline, amoxicillin/clavulanate); Probiotics: Lactobacillus PS128 Fecal transplant |
| **Miscellany** | Hepatic steatosis Chronic kidney failure Dysthyroidisms; Chronic lung disease |  | Kidney, liver, thyroid function female hormonal profile Spirometry, chest X-ray, chest CT | Specific treatments |
| **Commercial kits for persistent COVID diagnosis** |  |  | CheqUp; IncellKINE |  |

CT: Computed tomography; CMV: Cytomegalovirus; EMG: Electromyography; EBV: Epstein-Barr virus; GI: Gastrointestinal; MRI: Magnetic resonance imaging; PET: Positron emission tomography; PCR-RT: polymerase chain reaction reverse transcriptase; IgM: Immunoglobulin M; IgG: Immunoglobulin G.